nodes	percent_of_prediction	percent_of_DWPC	metapath
Ezogabine—UGT1A9—Mycophenolic acid—psoriasis	0.219	0.272	CbGbCtD
Ezogabine—UGT1A1—Mycophenolic acid—psoriasis	0.179	0.223	CbGbCtD
Ezogabine—UGT1A9—Mycophenolate mofetil—psoriasis	0.123	0.152	CbGbCtD
Ezogabine—CYP2A6—Methoxsalen—psoriasis	0.104	0.129	CbGbCtD
Ezogabine—UGT1A1—Mycophenolate mofetil—psoriasis	0.1	0.124	CbGbCtD
Ezogabine—CYP2A6—Prednisolone—psoriasis	0.0504	0.0626	CbGbCtD
Ezogabine—CYP2A6—Dexamethasone—psoriasis	0.0297	0.0369	CbGbCtD
Ezogabine—CYP2A6—CYP2E1 reactions—CYP2S1—psoriasis	0.000312	0.107	CbGpPWpGaD
Ezogabine—Ill-defined disorder—Cyclosporine—psoriasis	0.000287	0.0015	CcSEcCtD
Ezogabine—Osteoarthritis—Methotrexate—psoriasis	0.000284	0.00148	CcSEcCtD
Ezogabine—Tremor—Mycophenolate mofetil—psoriasis	0.000283	0.00148	CcSEcCtD
Ezogabine—Nausea—Acitretin—psoriasis	0.000282	0.00147	CcSEcCtD
Ezogabine—Nausea—Fluocinolone Acetonide—psoriasis	0.000281	0.00147	CcSEcCtD
Ezogabine—Paraesthesia—Mycophenolic acid—psoriasis	0.00028	0.00146	CcSEcCtD
Ezogabine—Ill-defined disorder—Mycophenolate mofetil—psoriasis	0.00028	0.00146	CcSEcCtD
Ezogabine—Malaise—Cyclosporine—psoriasis	0.000279	0.00146	CcSEcCtD
Ezogabine—Dyspnoea—Mycophenolic acid—psoriasis	0.000278	0.00145	CcSEcCtD
Ezogabine—Vertigo—Cyclosporine—psoriasis	0.000278	0.00145	CcSEcCtD
Ezogabine—Somnolence—Mycophenolic acid—psoriasis	0.000278	0.00145	CcSEcCtD
Ezogabine—Leukopenia—Cyclosporine—psoriasis	0.000277	0.00145	CcSEcCtD
Ezogabine—Mental disorder—Hydrocortisone—psoriasis	0.000277	0.00144	CcSEcCtD
Ezogabine—Malnutrition—Hydrocortisone—psoriasis	0.000275	0.00144	CcSEcCtD
Ezogabine—Dyspepsia—Mycophenolic acid—psoriasis	0.000275	0.00143	CcSEcCtD
Ezogabine—Neutropenia—Prednisone—psoriasis	0.000275	0.00143	CcSEcCtD
Ezogabine—Malaise—Mycophenolate mofetil—psoriasis	0.000272	0.00142	CcSEcCtD
Ezogabine—Vertigo—Mycophenolate mofetil—psoriasis	0.000271	0.00142	CcSEcCtD
Ezogabine—Syncope—Mycophenolate mofetil—psoriasis	0.000271	0.00141	CcSEcCtD
Ezogabine—Leukopenia—Mycophenolate mofetil—psoriasis	0.00027	0.00141	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.00027	0.00141	CcSEcCtD
Ezogabine—Fatigue—Mycophenolic acid—psoriasis	0.000269	0.0014	CcSEcCtD
Ezogabine—Hallucination—Dexamethasone—psoriasis	0.000269	0.0014	CcSEcCtD
Ezogabine—Hallucination—Betamethasone—psoriasis	0.000269	0.0014	CcSEcCtD
Ezogabine—Asthenia—Hydroxyurea—psoriasis	0.000268	0.0014	CcSEcCtD
Ezogabine—Weight increased—Prednisone—psoriasis	0.000267	0.0014	CcSEcCtD
Ezogabine—Constipation—Mycophenolic acid—psoriasis	0.000267	0.00139	CcSEcCtD
Ezogabine—Vision blurred—Prednisolone—psoriasis	0.000266	0.00139	CcSEcCtD
Ezogabine—Loss of consciousness—Mycophenolate mofetil—psoriasis	0.000265	0.00139	CcSEcCtD
Ezogabine—Anxiety—Cyclosporine—psoriasis	0.000263	0.00137	CcSEcCtD
Ezogabine—Liver function test abnormal—Methotrexate—psoriasis	0.000262	0.00137	CcSEcCtD
Ezogabine—Ill-defined disorder—Prednisolone—psoriasis	0.000261	0.00136	CcSEcCtD
Ezogabine—Discomfort—Cyclosporine—psoriasis	0.00026	0.00136	CcSEcCtD
Ezogabine—Visual impairment—Dexamethasone—psoriasis	0.00026	0.00136	CcSEcCtD
Ezogabine—Visual impairment—Betamethasone—psoriasis	0.00026	0.00136	CcSEcCtD
Ezogabine—Dry mouth—Cyclosporine—psoriasis	0.000258	0.00134	CcSEcCtD
Ezogabine—Feeling abnormal—Mycophenolic acid—psoriasis	0.000257	0.00134	CcSEcCtD
Ezogabine—Anxiety—Mycophenolate mofetil—psoriasis	0.000256	0.00134	CcSEcCtD
Ezogabine—Ill-defined disorder—Hydrocortisone—psoriasis	0.000255	0.00133	CcSEcCtD
Ezogabine—Confusional state—Cyclosporine—psoriasis	0.000255	0.00133	CcSEcCtD
Ezogabine—Malaise—Prednisolone—psoriasis	0.000254	0.00133	CcSEcCtD
Ezogabine—Discomfort—Mycophenolate mofetil—psoriasis	0.000254	0.00133	CcSEcCtD
Ezogabine—Vertigo—Prednisolone—psoriasis	0.000253	0.00132	CcSEcCtD
Ezogabine—Syncope—Prednisolone—psoriasis	0.000253	0.00132	CcSEcCtD
Ezogabine—Eye disorder—Dexamethasone—psoriasis	0.000252	0.00132	CcSEcCtD
Ezogabine—Eye disorder—Betamethasone—psoriasis	0.000252	0.00132	CcSEcCtD
Ezogabine—Dry mouth—Mycophenolate mofetil—psoriasis	0.000251	0.00131	CcSEcCtD
Ezogabine—Infection—Cyclosporine—psoriasis	0.000251	0.00131	CcSEcCtD
Ezogabine—Confusional state—Mycophenolate mofetil—psoriasis	0.000249	0.0013	CcSEcCtD
Ezogabine—Malaise—Hydrocortisone—psoriasis	0.000248	0.00129	CcSEcCtD
Ezogabine—Nervous system disorder—Cyclosporine—psoriasis	0.000248	0.00129	CcSEcCtD
Ezogabine—Loss of consciousness—Prednisolone—psoriasis	0.000248	0.00129	CcSEcCtD
Ezogabine—Thrombocytopenia—Cyclosporine—psoriasis	0.000247	0.00129	CcSEcCtD
Ezogabine—Vertigo—Hydrocortisone—psoriasis	0.000247	0.00129	CcSEcCtD
Ezogabine—Syncope—Hydrocortisone—psoriasis	0.000247	0.00129	CcSEcCtD
Ezogabine—Dizziness—Hydroxyurea—psoriasis	0.000247	0.00129	CcSEcCtD
Ezogabine—Infection—Mycophenolate mofetil—psoriasis	0.000245	0.00128	CcSEcCtD
Ezogabine—Hyperhidrosis—Cyclosporine—psoriasis	0.000244	0.00127	CcSEcCtD
Ezogabine—Shock—Mycophenolate mofetil—psoriasis	0.000243	0.00127	CcSEcCtD
Ezogabine—Loss of consciousness—Hydrocortisone—psoriasis	0.000242	0.00126	CcSEcCtD
Ezogabine—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000242	0.00126	CcSEcCtD
Ezogabine—Thrombocytopenia—Mycophenolate mofetil—psoriasis	0.000241	0.00126	CcSEcCtD
Ezogabine—Ill-defined disorder—Triamcinolone—psoriasis	0.00024	0.00125	CcSEcCtD
Ezogabine—Alopecia—Betamethasone—psoriasis	0.000239	0.00125	CcSEcCtD
Ezogabine—Alopecia—Dexamethasone—psoriasis	0.000239	0.00125	CcSEcCtD
Ezogabine—Hyperhidrosis—Mycophenolate mofetil—psoriasis	0.000238	0.00124	CcSEcCtD
Ezogabine—Discomfort—Prednisolone—psoriasis	0.000237	0.00124	CcSEcCtD
Ezogabine—Rash—Hydroxyurea—psoriasis	0.000235	0.00123	CcSEcCtD
Ezogabine—Dermatitis—Hydroxyurea—psoriasis	0.000235	0.00123	CcSEcCtD
Ezogabine—Hallucination—Prednisone—psoriasis	0.000234	0.00122	CcSEcCtD
Ezogabine—Malaise—Triamcinolone—psoriasis	0.000234	0.00122	CcSEcCtD
Ezogabine—Anxiety—Hydrocortisone—psoriasis	0.000233	0.00122	CcSEcCtD
Ezogabine—Vertigo—Triamcinolone—psoriasis	0.000233	0.00121	CcSEcCtD
Ezogabine—Syncope—Triamcinolone—psoriasis	0.000232	0.00121	CcSEcCtD
Ezogabine—Discomfort—Hydrocortisone—psoriasis	0.000231	0.00121	CcSEcCtD
Ezogabine—Dysuria—Methotrexate—psoriasis	0.00023	0.0012	CcSEcCtD
Ezogabine—Neutropenia—Methotrexate—psoriasis	0.00023	0.0012	CcSEcCtD
Ezogabine—Loss of consciousness—Triamcinolone—psoriasis	0.000228	0.00119	CcSEcCtD
Ezogabine—Paraesthesia—Cyclosporine—psoriasis	0.000227	0.00118	CcSEcCtD
Ezogabine—Shock—Prednisolone—psoriasis	0.000226	0.00118	CcSEcCtD
Ezogabine—Dyspnoea—Cyclosporine—psoriasis	0.000225	0.00118	CcSEcCtD
Ezogabine—Somnolence—Cyclosporine—psoriasis	0.000225	0.00117	CcSEcCtD
Ezogabine—Asthenia—Mycophenolic acid—psoriasis	0.000224	0.00117	CcSEcCtD
Ezogabine—Infection—Hydrocortisone—psoriasis	0.000223	0.00116	CcSEcCtD
Ezogabine—Dyspepsia—Cyclosporine—psoriasis	0.000222	0.00116	CcSEcCtD
Ezogabine—Hyperhidrosis—Prednisolone—psoriasis	0.000222	0.00116	CcSEcCtD
Ezogabine—Nausea—Hydroxyurea—psoriasis	0.000222	0.00116	CcSEcCtD
Ezogabine—Paraesthesia—Mycophenolate mofetil—psoriasis	0.000221	0.00115	CcSEcCtD
Ezogabine—Shock—Hydrocortisone—psoriasis	0.000221	0.00115	CcSEcCtD
Ezogabine—Nervous system disorder—Hydrocortisone—psoriasis	0.00022	0.00115	CcSEcCtD
Ezogabine—Eye disorder—Prednisone—psoriasis	0.00022	0.00115	CcSEcCtD
Ezogabine—Dyspnoea—Mycophenolate mofetil—psoriasis	0.00022	0.00115	CcSEcCtD
Ezogabine—Somnolence—Mycophenolate mofetil—psoriasis	0.000219	0.00114	CcSEcCtD
Ezogabine—Infestation NOS—Methotrexate—psoriasis	0.000219	0.00114	CcSEcCtD
Ezogabine—Infestation—Methotrexate—psoriasis	0.000219	0.00114	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000218	0.00114	CcSEcCtD
Ezogabine—Ill-defined disorder—Betamethasone—psoriasis	0.000218	0.00114	CcSEcCtD
Ezogabine—Ill-defined disorder—Dexamethasone—psoriasis	0.000218	0.00114	CcSEcCtD
Ezogabine—Discomfort—Triamcinolone—psoriasis	0.000218	0.00114	CcSEcCtD
Ezogabine—Fatigue—Cyclosporine—psoriasis	0.000218	0.00114	CcSEcCtD
Ezogabine—Hyperhidrosis—Hydrocortisone—psoriasis	0.000217	0.00113	CcSEcCtD
Ezogabine—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000217	0.00113	CcSEcCtD
Ezogabine—Constipation—Cyclosporine—psoriasis	0.000216	0.00113	CcSEcCtD
Ezogabine—Dry mouth—Triamcinolone—psoriasis	0.000216	0.00113	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000213	0.00111	CcSEcCtD
Ezogabine—Malaise—Betamethasone—psoriasis	0.000212	0.00111	CcSEcCtD
Ezogabine—Malaise—Dexamethasone—psoriasis	0.000212	0.00111	CcSEcCtD
Ezogabine—Vertigo—Dexamethasone—psoriasis	0.000211	0.0011	CcSEcCtD
Ezogabine—Vertigo—Betamethasone—psoriasis	0.000211	0.0011	CcSEcCtD
Ezogabine—Syncope—Dexamethasone—psoriasis	0.000211	0.0011	CcSEcCtD
Ezogabine—Syncope—Betamethasone—psoriasis	0.000211	0.0011	CcSEcCtD
Ezogabine—Constipation—Mycophenolate mofetil—psoriasis	0.000211	0.0011	CcSEcCtD
Ezogabine—Infection—Triamcinolone—psoriasis	0.00021	0.0011	CcSEcCtD
Ezogabine—Haematuria—Methotrexate—psoriasis	0.000209	0.00109	CcSEcCtD
Ezogabine—Feeling abnormal—Cyclosporine—psoriasis	0.000208	0.00109	CcSEcCtD
Ezogabine—Shock—Triamcinolone—psoriasis	0.000208	0.00109	CcSEcCtD
Ezogabine—Alopecia—Prednisone—psoriasis	0.000208	0.00108	CcSEcCtD
Ezogabine—Hepatobiliary disease—Methotrexate—psoriasis	0.000207	0.00108	CcSEcCtD
Ezogabine—Loss of consciousness—Dexamethasone—psoriasis	0.000207	0.00108	CcSEcCtD
Ezogabine—Loss of consciousness—Betamethasone—psoriasis	0.000207	0.00108	CcSEcCtD
Ezogabine—Dizziness—Mycophenolic acid—psoriasis	0.000207	0.00108	CcSEcCtD
Ezogabine—Paraesthesia—Prednisolone—psoriasis	0.000206	0.00108	CcSEcCtD
Ezogabine—Mental disorder—Prednisone—psoriasis	0.000206	0.00108	CcSEcCtD
Ezogabine—Malnutrition—Prednisone—psoriasis	0.000205	0.00107	CcSEcCtD
Ezogabine—Hyperhidrosis—Triamcinolone—psoriasis	0.000204	0.00107	CcSEcCtD
Ezogabine—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000203	0.00106	CcSEcCtD
Ezogabine—Paraesthesia—Hydrocortisone—psoriasis	0.000202	0.00105	CcSEcCtD
Ezogabine—Anxiety—Betamethasone—psoriasis	0.000199	0.00104	CcSEcCtD
Ezogabine—Anxiety—Dexamethasone—psoriasis	0.000199	0.00104	CcSEcCtD
Ezogabine—Discomfort—Dexamethasone—psoriasis	0.000198	0.00103	CcSEcCtD
Ezogabine—Discomfort—Betamethasone—psoriasis	0.000198	0.00103	CcSEcCtD
Ezogabine—Dyspepsia—Hydrocortisone—psoriasis	0.000198	0.00103	CcSEcCtD
Ezogabine—Rash—Mycophenolic acid—psoriasis	0.000197	0.00103	CcSEcCtD
Ezogabine—Dermatitis—Mycophenolic acid—psoriasis	0.000197	0.00103	CcSEcCtD
Ezogabine—Urinary tract disorder—Methotrexate—psoriasis	0.000194	0.00101	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000194	0.00101	CcSEcCtD
Ezogabine—Fatigue—Hydrocortisone—psoriasis	0.000194	0.00101	CcSEcCtD
Ezogabine—CYP2A6—Xenobiotics—CYP2S1—psoriasis	0.000193	0.0661	CbGpPWpGaD
Ezogabine—Vision blurred—Prednisone—psoriasis	0.000193	0.00101	CcSEcCtD
Ezogabine—Urethral disorder—Methotrexate—psoriasis	0.000193	0.00101	CcSEcCtD
Ezogabine—Infection—Dexamethasone—psoriasis	0.000191	0.000994	CcSEcCtD
Ezogabine—Infection—Betamethasone—psoriasis	0.000191	0.000994	CcSEcCtD
Ezogabine—Ill-defined disorder—Prednisone—psoriasis	0.00019	0.000991	CcSEcCtD
Ezogabine—Paraesthesia—Triamcinolone—psoriasis	0.00019	0.000991	CcSEcCtD
Ezogabine—Feeling abnormal—Prednisolone—psoriasis	0.000189	0.000989	CcSEcCtD
Ezogabine—Visual impairment—Methotrexate—psoriasis	0.000189	0.000988	CcSEcCtD
Ezogabine—Shock—Dexamethasone—psoriasis	0.000189	0.000985	CcSEcCtD
Ezogabine—Shock—Betamethasone—psoriasis	0.000189	0.000985	CcSEcCtD
Ezogabine—Dyspnoea—Triamcinolone—psoriasis	0.000189	0.000984	CcSEcCtD
Ezogabine—Nervous system disorder—Dexamethasone—psoriasis	0.000188	0.000982	CcSEcCtD
Ezogabine—Nervous system disorder—Betamethasone—psoriasis	0.000188	0.000982	CcSEcCtD
Ezogabine—Thrombocytopenia—Betamethasone—psoriasis	0.000188	0.00098	CcSEcCtD
Ezogabine—Thrombocytopenia—Dexamethasone—psoriasis	0.000188	0.00098	CcSEcCtD
Ezogabine—Dyspepsia—Triamcinolone—psoriasis	0.000186	0.000971	CcSEcCtD
Ezogabine—Nausea—Mycophenolic acid—psoriasis	0.000186	0.000968	CcSEcCtD
Ezogabine—Hyperhidrosis—Dexamethasone—psoriasis	0.000185	0.000968	CcSEcCtD
Ezogabine—Hyperhidrosis—Betamethasone—psoriasis	0.000185	0.000968	CcSEcCtD
Ezogabine—Feeling abnormal—Hydrocortisone—psoriasis	0.000185	0.000966	CcSEcCtD
Ezogabine—Malaise—Prednisone—psoriasis	0.000185	0.000963	CcSEcCtD
Ezogabine—Vertigo—Prednisone—psoriasis	0.000184	0.00096	CcSEcCtD
Ezogabine—Eye disorder—Methotrexate—psoriasis	0.000184	0.000958	CcSEcCtD
Ezogabine—Syncope—Prednisone—psoriasis	0.000184	0.000958	CcSEcCtD
Ezogabine—Fatigue—Triamcinolone—psoriasis	0.000182	0.000951	CcSEcCtD
Ezogabine—Asthenia—Cyclosporine—psoriasis	0.000181	0.000946	CcSEcCtD
Ezogabine—Loss of consciousness—Prednisone—psoriasis	0.00018	0.000939	CcSEcCtD
Ezogabine—Asthenia—Mycophenolate mofetil—psoriasis	0.000177	0.000923	CcSEcCtD
Ezogabine—Feeling abnormal—Triamcinolone—psoriasis	0.000174	0.000909	CcSEcCtD
Ezogabine—Anxiety—Prednisone—psoriasis	0.000174	0.000906	CcSEcCtD
Ezogabine—Alopecia—Methotrexate—psoriasis	0.000174	0.000906	CcSEcCtD
Ezogabine—Paraesthesia—Dexamethasone—psoriasis	0.000172	0.000899	CcSEcCtD
Ezogabine—Paraesthesia—Betamethasone—psoriasis	0.000172	0.000899	CcSEcCtD
Ezogabine—Discomfort—Prednisone—psoriasis	0.000172	0.000898	CcSEcCtD
Ezogabine—Mental disorder—Methotrexate—psoriasis	0.000172	0.000898	CcSEcCtD
Ezogabine—Malnutrition—Methotrexate—psoriasis	0.000171	0.000893	CcSEcCtD
Ezogabine—Dyspepsia—Betamethasone—psoriasis	0.000169	0.000881	CcSEcCtD
Ezogabine—Dyspepsia—Dexamethasone—psoriasis	0.000169	0.000881	CcSEcCtD
Ezogabine—Dizziness—Cyclosporine—psoriasis	0.000167	0.000872	CcSEcCtD
Ezogabine—Infection—Prednisone—psoriasis	0.000166	0.000866	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000166	0.000864	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Betamethasone—psoriasis	0.000166	0.000864	CcSEcCtD
Ezogabine—Fatigue—Betamethasone—psoriasis	0.000165	0.000863	CcSEcCtD
Ezogabine—Fatigue—Dexamethasone—psoriasis	0.000165	0.000863	CcSEcCtD
Ezogabine—Shock—Prednisone—psoriasis	0.000164	0.000858	CcSEcCtD
Ezogabine—Nervous system disorder—Prednisone—psoriasis	0.000164	0.000855	CcSEcCtD
Ezogabine—Dizziness—Mycophenolate mofetil—psoriasis	0.000163	0.00085	CcSEcCtD
Ezogabine—Hyperhidrosis—Prednisone—psoriasis	0.000162	0.000843	CcSEcCtD
Ezogabine—Vision blurred—Methotrexate—psoriasis	0.000161	0.000841	CcSEcCtD
Ezogabine—Asthenia—Hydrocortisone—psoriasis	0.000161	0.000841	CcSEcCtD
Ezogabine—Rash—Cyclosporine—psoriasis	0.000159	0.000831	CcSEcCtD
Ezogabine—Dermatitis—Cyclosporine—psoriasis	0.000159	0.00083	CcSEcCtD
Ezogabine—Ill-defined disorder—Methotrexate—psoriasis	0.000159	0.000828	CcSEcCtD
Ezogabine—Feeling abnormal—Dexamethasone—psoriasis	0.000158	0.000825	CcSEcCtD
Ezogabine—Feeling abnormal—Betamethasone—psoriasis	0.000158	0.000825	CcSEcCtD
Ezogabine—Rash—Mycophenolate mofetil—psoriasis	0.000155	0.000811	CcSEcCtD
Ezogabine—Dermatitis—Mycophenolate mofetil—psoriasis	0.000155	0.00081	CcSEcCtD
Ezogabine—Malaise—Methotrexate—psoriasis	0.000154	0.000805	CcSEcCtD
Ezogabine—Vertigo—Methotrexate—psoriasis	0.000154	0.000802	CcSEcCtD
Ezogabine—Leukopenia—Methotrexate—psoriasis	0.000153	0.000799	CcSEcCtD
Ezogabine—Dizziness—Prednisolone—psoriasis	0.000152	0.000793	CcSEcCtD
Ezogabine—Asthenia—Triamcinolone—psoriasis	0.000152	0.000792	CcSEcCtD
Ezogabine—Nausea—Cyclosporine—psoriasis	0.00015	0.000783	CcSEcCtD
Ezogabine—Paraesthesia—Prednisone—psoriasis	0.00015	0.000783	CcSEcCtD
Ezogabine—Dizziness—Hydrocortisone—psoriasis	0.000148	0.000775	CcSEcCtD
Ezogabine—Dyspepsia—Prednisone—psoriasis	0.000147	0.000767	CcSEcCtD
Ezogabine—Nausea—Mycophenolate mofetil—psoriasis	0.000146	0.000764	CcSEcCtD
Ezogabine—Rash—Prednisolone—psoriasis	0.000145	0.000756	CcSEcCtD
Ezogabine—Dermatitis—Prednisolone—psoriasis	0.000145	0.000756	CcSEcCtD
Ezogabine—Fatigue—Prednisone—psoriasis	0.000144	0.000752	CcSEcCtD
Ezogabine—Discomfort—Methotrexate—psoriasis	0.000144	0.000751	CcSEcCtD
Ezogabine—Constipation—Prednisone—psoriasis	0.000143	0.000745	CcSEcCtD
Ezogabine—Rash—Hydrocortisone—psoriasis	0.000142	0.000739	CcSEcCtD
Ezogabine—Dermatitis—Hydrocortisone—psoriasis	0.000141	0.000738	CcSEcCtD
Ezogabine—Confusional state—Methotrexate—psoriasis	0.000141	0.000735	CcSEcCtD
Ezogabine—Dizziness—Triamcinolone—psoriasis	0.00014	0.00073	CcSEcCtD
Ezogabine—Infection—Methotrexate—psoriasis	0.000139	0.000724	CcSEcCtD
Ezogabine—Feeling abnormal—Prednisone—psoriasis	0.000138	0.000718	CcSEcCtD
Ezogabine—Asthenia—Betamethasone—psoriasis	0.000138	0.000718	CcSEcCtD
Ezogabine—Asthenia—Dexamethasone—psoriasis	0.000138	0.000718	CcSEcCtD
Ezogabine—Nervous system disorder—Methotrexate—psoriasis	0.000137	0.000714	CcSEcCtD
Ezogabine—Thrombocytopenia—Methotrexate—psoriasis	0.000137	0.000713	CcSEcCtD
Ezogabine—Nausea—Prednisolone—psoriasis	0.000137	0.000713	CcSEcCtD
Ezogabine—Hyperhidrosis—Methotrexate—psoriasis	0.000135	0.000704	CcSEcCtD
Ezogabine—Nausea—Hydrocortisone—psoriasis	0.000133	0.000696	CcSEcCtD
Ezogabine—Rash—Triamcinolone—psoriasis	0.000133	0.000696	CcSEcCtD
Ezogabine—Dermatitis—Triamcinolone—psoriasis	0.000133	0.000695	CcSEcCtD
Ezogabine—NAT2—Biological oxidations—CYP2S1—psoriasis	0.000129	0.0441	CbGpPWpGaD
Ezogabine—NAT2—Metapathway biotransformation—CYP2S1—psoriasis	0.000127	0.0435	CbGpPWpGaD
Ezogabine—Dizziness—Betamethasone—psoriasis	0.000127	0.000662	CcSEcCtD
Ezogabine—Dizziness—Dexamethasone—psoriasis	0.000127	0.000662	CcSEcCtD
Ezogabine—Nausea—Triamcinolone—psoriasis	0.000126	0.000655	CcSEcCtD
Ezogabine—Paraesthesia—Methotrexate—psoriasis	0.000125	0.000654	CcSEcCtD
Ezogabine—Dyspnoea—Methotrexate—psoriasis	0.000124	0.00065	CcSEcCtD
Ezogabine—Somnolence—Methotrexate—psoriasis	0.000124	0.000648	CcSEcCtD
Ezogabine—Dyspepsia—Methotrexate—psoriasis	0.000123	0.000641	CcSEcCtD
Ezogabine—Rash—Betamethasone—psoriasis	0.000121	0.000631	CcSEcCtD
Ezogabine—Rash—Dexamethasone—psoriasis	0.000121	0.000631	CcSEcCtD
Ezogabine—Dermatitis—Dexamethasone—psoriasis	0.000121	0.000631	CcSEcCtD
Ezogabine—Dermatitis—Betamethasone—psoriasis	0.000121	0.000631	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Methotrexate—psoriasis	0.000121	0.000629	CcSEcCtD
Ezogabine—Fatigue—Methotrexate—psoriasis	0.00012	0.000628	CcSEcCtD
Ezogabine—Asthenia—Prednisone—psoriasis	0.00012	0.000625	CcSEcCtD
Ezogabine—Feeling abnormal—Methotrexate—psoriasis	0.000115	0.0006	CcSEcCtD
Ezogabine—Nausea—Dexamethasone—psoriasis	0.000114	0.000595	CcSEcCtD
Ezogabine—Nausea—Betamethasone—psoriasis	0.000114	0.000595	CcSEcCtD
Ezogabine—Dizziness—Prednisone—psoriasis	0.00011	0.000576	CcSEcCtD
Ezogabine—Rash—Prednisone—psoriasis	0.000105	0.00055	CcSEcCtD
Ezogabine—Dermatitis—Prednisone—psoriasis	0.000105	0.000549	CcSEcCtD
Ezogabine—Asthenia—Methotrexate—psoriasis	0.0001	0.000523	CcSEcCtD
Ezogabine—Nausea—Prednisone—psoriasis	9.92e-05	0.000518	CcSEcCtD
Ezogabine—Dizziness—Methotrexate—psoriasis	9.23e-05	0.000482	CcSEcCtD
Ezogabine—Rash—Methotrexate—psoriasis	8.8e-05	0.000459	CcSEcCtD
Ezogabine—Dermatitis—Methotrexate—psoriasis	8.8e-05	0.000459	CcSEcCtD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	8.7e-05	0.0298	CbGpPWpGaD
Ezogabine—Nausea—Methotrexate—psoriasis	8.29e-05	0.000433	CcSEcCtD
Ezogabine—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	8.03e-05	0.0275	CbGpPWpGaD
Ezogabine—CYP2A6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	7.92e-05	0.0271	CbGpPWpGaD
Ezogabine—UGT1A4—Biological oxidations—CYP2S1—psoriasis	7.81e-05	0.0267	CbGpPWpGaD
Ezogabine—UGT1A4—Metapathway biotransformation—CYP2S1—psoriasis	7.7e-05	0.0263	CbGpPWpGaD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	7.23e-05	0.0247	CbGpPWpGaD
Ezogabine—CYP2A6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	6.51e-05	0.0223	CbGpPWpGaD
Ezogabine—UGT1A3—Biological oxidations—CYP2S1—psoriasis	6.49e-05	0.0222	CbGpPWpGaD
Ezogabine—UGT1A3—Metapathway biotransformation—CYP2S1—psoriasis	6.4e-05	0.0219	CbGpPWpGaD
Ezogabine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	5.03e-05	0.0172	CbGpPWpGaD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	5e-05	0.0171	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	5e-05	0.0171	CbGpPWpGaD
Ezogabine—UGT1A1—Biological oxidations—CYP2S1—psoriasis	4.49e-05	0.0153	CbGpPWpGaD
Ezogabine—UGT1A9—Biological oxidations—CYP2S1—psoriasis	4.49e-05	0.0153	CbGpPWpGaD
Ezogabine—UGT1A1—Metapathway biotransformation—CYP2S1—psoriasis	4.42e-05	0.0151	CbGpPWpGaD
Ezogabine—UGT1A9—Metapathway biotransformation—CYP2S1—psoriasis	4.42e-05	0.0151	CbGpPWpGaD
Ezogabine—UGT1A4—NRF2 pathway—TGFA—psoriasis	4.35e-05	0.0149	CbGpPWpGaD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	3.74e-05	0.0128	CbGpPWpGaD
Ezogabine—UGT1A3—NRF2 pathway—TGFA—psoriasis	3.61e-05	0.0124	CbGpPWpGaD
Ezogabine—CYP2A6—Biological oxidations—CYP2S1—psoriasis	3.46e-05	0.0118	CbGpPWpGaD
Ezogabine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	3.33e-05	0.0114	CbGpPWpGaD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	3.23e-05	0.0111	CbGpPWpGaD
Ezogabine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	3.21e-05	0.011	CbGpPWpGaD
Ezogabine—UGT1A9—PPARA activates gene expression—CARM1—psoriasis	3.13e-05	0.0107	CbGpPWpGaD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	3.11e-05	0.0106	CbGpPWpGaD
Ezogabine—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	3.07e-05	0.0105	CbGpPWpGaD
Ezogabine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	2.91e-05	0.00996	CbGpPWpGaD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	2.69e-05	0.00919	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—NDUFA5—psoriasis	2.59e-05	0.00886	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—CARM1—psoriasis	2.54e-05	0.0087	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—CARM1—psoriasis	2.54e-05	0.0087	CbGpPWpGaD
Ezogabine—UGT1A1—NRF2 pathway—TGFA—psoriasis	2.5e-05	0.00854	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—TGFA—psoriasis	2.5e-05	0.00854	CbGpPWpGaD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	2.42e-05	0.00828	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—CYP2S1—psoriasis	2.2e-05	0.00754	CbGpPWpGaD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	2.15e-05	0.00735	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	2.15e-05	0.00735	CbGpPWpGaD
Ezogabine—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	2.11e-05	0.00722	CbGpPWpGaD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	2.01e-05	0.00688	CbGpPWpGaD
Ezogabine—CYP2A6—NRF2 pathway—TGFA—psoriasis	1.92e-05	0.00658	CbGpPWpGaD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	1.86e-05	0.00635	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	1.86e-05	0.00635	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—NDUFA5—psoriasis	1.57e-05	0.00537	CbGpPWpGaD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	1.39e-05	0.00476	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	1.39e-05	0.00476	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—CYP2S1—psoriasis	1.34e-05	0.00457	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—NDUFA5—psoriasis	1.31e-05	0.00446	CbGpPWpGaD
Ezogabine—UGT1A9—PPARA activates gene expression—PPARG—psoriasis	1.3e-05	0.00446	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—TYK2—psoriasis	1.3e-05	0.00445	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—TYK2—psoriasis	1.3e-05	0.00445	CbGpPWpGaD
Ezogabine—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	1.28e-05	0.00436	CbGpPWpGaD
Ezogabine—CYP2A6—Fluoropyrimidine Activity—TP53—psoriasis	1.23e-05	0.00422	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—LEP—psoriasis	1.22e-05	0.00416	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—LEP—psoriasis	1.22e-05	0.00416	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—CYP2S1—psoriasis	1.11e-05	0.0038	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—CARM1—psoriasis	1.08e-05	0.00368	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—PPARG—psoriasis	1.06e-05	0.00362	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—PPARG—psoriasis	1.06e-05	0.00362	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—TYK2—psoriasis	9.28e-06	0.00317	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—TYK2—psoriasis	9.28e-06	0.00317	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—VEGFA—psoriasis	9.2e-06	0.00315	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—VEGFA—psoriasis	9.2e-06	0.00315	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—NDUFA5—psoriasis	9.02e-06	0.00308	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—NDUFA5—psoriasis	9.02e-06	0.00308	CbGpPWpGaD
Ezogabine—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	8.79e-06	0.00301	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	8.41e-06	0.00288	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CYP2S1—psoriasis	7.67e-06	0.00262	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CYP2S1—psoriasis	7.67e-06	0.00262	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—NFKB1—psoriasis	7.23e-06	0.00247	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—NFKB1—psoriasis	7.23e-06	0.00247	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—NDUFA5—psoriasis	6.95e-06	0.00238	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—CAT—psoriasis	6.62e-06	0.00226	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—VEGFA—psoriasis	6.56e-06	0.00224	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—VEGFA—psoriasis	6.56e-06	0.00224	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—CARM1—psoriasis	6.52e-06	0.00223	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—STAT3—psoriasis	6.5e-06	0.00222	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—STAT3—psoriasis	6.5e-06	0.00222	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—IL6—psoriasis	6.36e-06	0.00218	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—IL6—psoriasis	6.36e-06	0.00218	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CYP2S1—psoriasis	5.91e-06	0.00202	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—TNF—psoriasis	5.63e-06	0.00192	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—TNF—psoriasis	5.63e-06	0.00192	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—CARM1—psoriasis	5.42e-06	0.00185	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—APOE—psoriasis	5.14e-06	0.00176	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—IL6—psoriasis	4.54e-06	0.00155	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—IL6—psoriasis	4.54e-06	0.00155	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PPARG—psoriasis	4.48e-06	0.00153	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.02e-06	0.00137	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—CAT—psoriasis	4.01e-06	0.00137	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CARM1—psoriasis	3.75e-06	0.00128	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CARM1—psoriasis	3.75e-06	0.00128	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.5e-06	0.0012	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—CAT—psoriasis	3.33e-06	0.00114	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—APOE—psoriasis	3.12e-06	0.00107	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CARM1—psoriasis	2.89e-06	0.000987	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PPARG—psoriasis	2.71e-06	0.000928	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—APOE—psoriasis	2.59e-06	0.000886	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CAT—psoriasis	2.3e-06	0.000788	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CAT—psoriasis	2.3e-06	0.000788	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PPARG—psoriasis	2.26e-06	0.000772	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—APOE—psoriasis	1.79e-06	0.000612	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—APOE—psoriasis	1.79e-06	0.000612	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CAT—psoriasis	1.78e-06	0.000607	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PPARG—psoriasis	1.56e-06	0.000533	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PPARG—psoriasis	1.56e-06	0.000533	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—APOE—psoriasis	1.38e-06	0.000472	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PPARG—psoriasis	1.2e-06	0.000411	CbGpPWpGaD
